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Intravenous injection of therapeutics is required to eﬀectively treat or cure metastatic cancer, certain cardiovascular diseases, and
otheracquiredorinheriteddiseases.Usingthisrouteofdeliveryallowspotentialuptakeinalldiseasetargetsthatareaccessedbythe
bloodstream. However, normal tissues and organs also have the potential for uptake of therapeutic agents. Therefore, investigators
have used targeted delivery to attempt delivery solely to the target cells; however, use of ligands on the surface of delivery vehicles
to target speciﬁc cell surface receptors is not suﬃcient to avoid nonspeciﬁc uptake. PEGylation has been used for decades to try
to avoid nonspeciﬁc uptake but suﬀers from many problems known as “The PEGylation Dilemma.” We have solved this dilemma
by replacing PEGylation with reversible masking using low-molecular-weight neutral lipids in order to achieve optimal-targeted
delivery solely to target cells. Our paper will focus on this topic.
1.Introduction
Weusebilamellar-invaginatedvesicles(BIVs)thatareunique
liposomal nanoparticles (NPs) providing highly eﬃcient
delivery for intravenous (iv) injection of encapsulated
therapeutics including plasmid DNA [1–5]. In addition
to having extended half-life and stability in circulation,
BIVs are nontoxic, nonimmunogenic, biodegradable and
can be repeatedly administered without losing potency.
Furthermore, BIVs encapsulating therapeutic agents can be
modiﬁedtospeciﬁcallytargetentryintothediseasecellusing
small molecules that mimic beta turns incorporated on the
surfaceofBIVcomplexes whilebypassing nonspeciﬁcuptake
using reversible masking. Although BIV-DNA complexes
have already been used successfully in clinical trials to treat
metastatic lung cancer [6] and hereditary inclusion body
myopathy [7, 8], in the former a ﬁrst-pass uptake in the
involved lungs obviated the need for diﬀerential tumor
targeting and, in the latter, the goal of increased production
of sialic acid required merely an organ repository. However,
reversible masking was designed to be used with BIVs
as well as other delivery systems to focus target-speciﬁc
biodistribution, for example, metastatic cancer, by bypassing
nonspeciﬁc uptake post-iv injections. The aim of this review
is to deﬁne and distinguish our novel reversible masking
versus PEGylation and demonstrate its superior use for
avoiding nonspeciﬁc uptake in vivo.
2.OptimizationofCationicLiposome
Formulations for Use In Vivo
Much research has been directed toward the synthesis of new
cationic lipids. Some new formulations enable more eﬃcient
transfection of cells in culture. However, their eﬃciency
measured in vitro did not correlate with their ability to
deliver DNA after administration in animals. Functional
properties deﬁned in vitro do not assess the stability of
the complexes in plasma or their pharmacokinetics and
biodistribution, all of which are essential for optimal activity
in vivo. Colloidal properties of the complexes, in addition
to the physicochemical properties of their component lipids,
also determine these parameters. In particular, in addition
to eﬃcient transfection of target cells, nucleic acid-liposome2 Journal of Drug Delivery
c o m p l e x e sm u s tb ea b l et ot r a v e r s et i g h tb a r r i e r si nv i v oa n d
penetrate throughout the target tissue to produce eﬃcacy for
the treatment of disease, that is, countercurrent to increased
intratumoral pressure gradients for the treatment of cancer.
These are not issues for achieving eﬃcient transfection
of cells in culture with the exception of polarized tissue
culture cells. Therefore, we are not surprised that optimized
liposomal delivery vehicles for use in vivo may be diﬀerent
than those used for eﬃcient delivery to some cells in culture.
In summary, in vivo nucleic acid-liposome complexes
that produce eﬃcacy in animal models of disease have
extended half-life in the circulation, are stable in serum,
have broad biodistribution that can be focused, eﬃciently
encapsulate various sizes of nucleic acids, are targetable
to speciﬁc organs and cell types, penetrate across tight
barriers in several organs, penetrate evenly throughout the
target tissue, are optimized for nucleic acid:lipid ratio and
colloidal suspension in vivo, can be size fractionated to
produce a homogenous population of complexes prior to
injection, and can be repeatedly administered. Recently,
we demonstrated eﬃcacy of a robust liposomal delivery
system in small and large animal models for lung [18],
breast [19], head and neck, and pancreatic cancers [20–
22], and for Hepatitis B and C [23]. Based on eﬃcacy
in these animal studies, this liposomal delivery system has
been used successfully in phase I clinical trials to treat end-
stage nonsmall cell lung carcinoma patients who have failed
to respond to chemotherapy [6] and hereditary inclusion
body myopathy [7, 8]. The nonsmall cell lung carcinoma
patients have prolonged life spans and have demonstrated
objective responses including tumor regression. Eﬃcacy was
also demonstrated for the single patient trials for hereditary
inclusion body myopathy. The BIV delivery system will also
be used in upcoming clinical trials to treat other types
of cancer including pancreatic, breast, and head and neck
cancers. Our studies have demonstrated broad eﬃcacy in the
use of liposomes to treat disease and have dispelled several
myths that exist concerning the use of liposomal systems.
3. Liposome Morphology and Effects on
GeneDeliveryandExpression
Eﬃcient in vivo nucleic acid-liposome complexes have
unique features including their morphology, mechanisms
for crossing the cell membrane and entry into the nucleus,
ability to be targeted for delivery to speciﬁc cell surface
receptors, and ability to penetrate across tight barriers and
throughout target tissues. Liposomes have diﬀerent mor-
phologiesbasedupontheircompositionandtheformulation
method. Furthermore, the morphology of complexes can
contribute to their ability to deliver nucleic acids in vivo.
Formulationsfrequentlyusedforthedeliveryofnucleicacids
are lamellar structures including small unilamellar vesicles
(SUVs), multilamellar vesicles (MLVs), or the bilamellar
invaginated vesicles (BIVs) recently developed in our labora-
tory Figure 1. Several investigators have developed liposomal
delivery systems using hexagonal structures; however, they
have demonstrated eﬃciency primarily for the transfection
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Figure 1 :D i a g r a m sd r a w nf r o mc r y o - e l e c t r o nm i c r o g r a p h so f
cross-sections through vitriﬁed ﬁlms of various types of liposomes
and DNA-liposome complexes. SUVs are small unilamellar vesicles
that condense nucleic acids on the surface and produce “spaghetti
and meatballs” structures. MLVs are multilamellar vesicles that
appear as “Swiss rolls” after mixing with DNA. BIVs are bilamellar-
invaginated vesicles produced using a formulation developed in our
laboratory [1]. Nucleic acids are eﬃciently encapsulated between
two bilamellar-invaginated structures (BIVs).
o fs o m ec e l lt y p e si nc u l t u r ea n dn o tf o ri nv i v od e l i v e r y .
SUVs condense nucleic acids on the surface and form
“spaghetti and meatballs” structures [24]. DNA-liposome
complexes made using SUVs produce little or no gene
expression upon systemic delivery, although these complexes
transfect numerous cell types eﬃciently in vitro [25, 26].
Furthermore, SUV liposome-DNA complexes cannot be
targeted eﬃciently. SUV liposome-DNA complexes also have
a short half-life within the circulation, generally about 5
to 10 minutes. Polyethylene glycol (PEG) has been added
to liposome formulations to extend their half-life [27–29];
however, PEGylation creates other problems that have not as
yet been resolved. PEG seems to hinder delivery of cationic
liposomes into cells due to its sterically hindering ionic
interactions, and it interferes with optimal condensation of
nucleic acids onto the cationic delivery vehicle. Furthermore,
the resultant extremely long half-life in the circulation, for
example, up to several days, has caused problems for patients
as illustrated by the increased percentage of injected dose of
the PEGylated liposomal formulation doxil that encapsulates
the cytotoxic agent, doxorubicin, which accumulates in the
skin, hands, and feet resulting in mucositis and hand and
foot syndrome [30, 31] that cause extreme discomfort to
the patient. Attempts to add ligands to doxil for delivery toJournal of Drug Delivery 3
speciﬁc cell surface receptors have not resulted in much cell-
speciﬁc delivery, and an increased percentage of the injected
targetedformulationstillaccumulatesintheskin,hands,and
feet. Addition of PEG into formulations developed in our
laboratory also caused steric hindrance in the bilamellar-
invaginated structures that hindered DNA encapsulation,
and gene expression was substantially diminished. Recent
eﬀorts to use cleavable PEG are unimpressive and have not
solved these problems [10, 12–17, 32]. The vast majority
of the injected PEGylated complexes bypass the target cell,
including those using cleavable PEG.
Some investigators have loaded nucleic acids into SUVs
using a variety of methods; however, the bulk of the DNA
does not load or stay within the liposomes. Furthermore,
most of the processes used for loading nucleic acids within
liposomes are extremely time-consuming and not cost-
eﬀective. Therefore, SUVs are not the ideal liposomes for
creating nonviral vehicles for targeted delivery.
Complexes made using MLVs appear as “Swiss rolls”
when viewing cross-sections by cryo-electron microscopy
[33] .T h e s ec o m p l e x e sc a nb e c o m et o ol a r g ef o rs y s t e m i c
administration or deliver nucleic acids ineﬃciently into cells
due to inability to “unravel” at the cell surface. Addition
of ligands onto MLV liposome-DNA complexes further
aggravates these problems. Therefore, MLVs are not useful
for the development of targeted delivery of nucleic acids.
Using a formulation developed in our laboratory, nu-
cleic acids are eﬃciently encapsulated between two bila-
mellar invaginated vesicles, BIVs [1]. We created these
unique structures using 1,2-bis(oleoyloxy)-3-(trimethyl-
ammino)propane (DOTAP) and synthetic cholesterol
(Chol) and a novel formulation procedure. This procedure is
diﬀerentbecauseitincludesabrief,low-frequencysonication
followed by manual extrusion through ﬁlters of decreasing
pore size. The 0.1 and 0.2um ﬁlters used are made of
aluminum oxide and not polycarbonate that is typically used
by other protocols. Aluminum oxide membranes contain
more pores per surface area that are evenly spaced and sized
and have straight channels. During the manual extrusion
process, the liposomes are passed through each of four
diﬀerent sized ﬁlters only once. This process produces 88%
invaginated liposomes. Use of high frequency sonication
and/or mechanical extrusion produces only SUVs.
BIVs condense unusually large amounts of nucleic acids
of any size Figure 2 as well as viruses Figure 3. Furthermore,
addition of other DNA condensing agents including poly-
mers is not necessary. For example, condensation of plasmid
DNA onto polymers prior to encapsulation in the BIVs did
not increase condensation or subsequent gene expression
after transfection in vitro or in vivo. Encapsulation of nucleic
acids by these BIVs alone is spontaneous and immediate,
and, therefore, cost-eﬀective requiring only one step of
simplemixing.TheextrudedBIVDOTAP:Chol-nucleicacid
complexes are also large enough so that they are not cleared
rapidly by Kupﬀer cells in the liver and yet extravasate
across tight barriers, including the endothelial cell barrier
of the lungs in a normal mouse, and diﬀuse through target
organs eﬃciently [18]. Our work demonstrating eﬃcacy for
treatment of nonsmall cell lung cancer [18] showed that only
4 nm
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4 nm
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Figure 2: Proposed model showing cross-sections of extruded
DOTAP: Chol liposomes (BIVs) interacting with nucleic acids.
Nucleic acids adsorb onto a BIV via electrostatic interactions.
Attraction of a second BIV to this complex results in further charge
neutralization. Expanding electrostatic interactions with nucleic
acids causes inversion of the larger BIV and total encapsulation of
the nucleic acids. Inversion can occur in these liposomes because
of their excess surface area, which allows them to accommodate
the stress created by the nucleic acid-lipid interactions. Nucleic
acid binding reduces the surface area of the outer leaﬂet of the
bilayer and induces the negative curvature due to lipid ordering and
reduction of charge repulsion between cationic lipid headgroups.
Condensation of the internalized nucleic acid-lipid sandwich
expands the space between the bilayers and may induce membrane
fusion to generate the apparently closed structures. The enlarged
areashowsthearrangementofnucleicacidscondensedbetweentwo
4nm bilayers of extruded DOTAP:Chol.
BIV DOTAP:Chol-p53 DNA liposome complexes produced
eﬃcacy; whereas SUV DOTAP:Chol-p53 DNA liposome
complexes produced no eﬃcacy. Therefore, the choice of
lipids alone is not suﬃcient for optimal DNA delivery, and
the morphology of the complexes is essential.
4. Optimal LipidsandLiposome Morphology:
Effects on Gene Delivery and Expression
Choosing the best cationic lipids and neutral lipids are also
essential for producing the optimal in vivo formulation. For
example, using our novel manual extrusion procedure does
not produce BIVs using the cationic lipid dimethyldioctade-
cylammonium bromide (DDAB). Furthermore, DOTAP is
biodegradable, whereas DDAB is not biodegradable. Use of
biodegradable lipids is preferred for use in humans. Further-
more, only DOTAP and not DDAB containing liposomes
produced highly eﬃcient gene expression in vivo [1]. DDAB
did not produce BIVs and was unable to encapsulate nucleic
acids. Apparently, DDAB and DOTAP containing SUVs
produce similar eﬃciency of gene delivery in vivo; however,
these SUVs are not as eﬃcient as BIV DOTAP:Chol [1].
In addition, use of L-α dioleoyl phosphatidylethanolamine
(DOPE) as a neutral lipid creates liposomes that cannot
wrap or encapsulate nucleic acids. Several investigators have
reported eﬃcient transfection of cells in culture using DOPE4 Journal of Drug Delivery
Assembly of BIV + adenovirus complexes
Figure 3: Proposed model showing cross-sections of an extruded
DOTAP:Chol liposome (BIV) interacting with adenovirus. Ade-
novirus interacts with a BIV causing negative curvature and
wrapping around the virus particle.
in liposomal formulations. However, our data showed that
formulations consisting of DOPE were not eﬃcient for
producing gene expression in vivo [1].
Investigators must also consider the source and lot
variability of certain lipids purchased from companies. For
example, diﬀerent lots of natural cholesterol from the same
vendor can vary dramatically and will aﬀect the formulation
of liposomes. We use synthetic cholesterol instead of natural
cholesterol that is puriﬁed from the wool of sheep. Synthetic
cholesterol is required by the Food and Drug Administration
for use in producing therapeutics for injection into humans.
Our BIV formulations are also stable for a few years as
liquid suspensions. Freeze-dried formulations can also be
made that are stable indeﬁnitely even at room temperature.
Stability of liposomes and liposomal complexes is also
essential particularly for the commercial development of
human therapeutics.
5. Liposome Encapsulation,Flexibility,and
Optimal Colloidal Suspensions
A common belief is that artiﬁcial vehicles must be 100nm
or smaller to be eﬀective for systemic delivery. However, this
belief is most likely true only for large, inﬂexible delivery
vehicles. Blood cells are several microns (up to 7000nm)
in size and yet have no diﬃculty circulating in the blood
including through the smallest capillaries. However, sickle
cell blood cells, that are rigid, do have problems in the
circulation. Therefore, we believe that ﬂexibility is a more
important issue than small size. In fact, BIV DNA-liposome
complexes in the size range of 200 to 450nm produced the
highestlevelsofgeneexpressioninalltissuesafterivinjection
[1]. Delivery vehicles, including nonviral vectors and viruses,
that are not PEGylated and are smaller than 200nm are
cleared quickly by the Kupﬀer cells in the liver. Therefore,
Figure 4: Cryo-electron micrograph of BIV DOTAP:Chol-DNA
liposome complexes. The plasmid DNA is encapsulated between
two BIVs.
increased size of liposomal complexes could extend their
circulation time particularly when combined with injection
of high colloidal suspensions. BIVs are able to encapsulate
nucleic acids and viruses apparently due to the presence of
cholesterol in the bilayer (Figure 4). Formulations including
DOPEinsteadofcholesterolcouldnotassemblenucleicacids
bya“wrappingtype”ofmechanism(Figure 5)andpr oduc ed
little gene expression in the lungs and no expression in other
tissues after intravenous injections. Because the extruded
DOTAP:Chol BIV complexes are ﬂexible and not rigid, are
stable in high concentrations of serum, and have extended
half-life, they do not have diﬃculty circulating eﬃciently in
the bloodstream.
We believe that colloidal properties of nucleic acid-
liposome complexes also determine the levels of gene
expression produced after in vivo delivery [1, 34]. These
properties include the DNA:lipid ratio that determines the
overall charge density of the complexes and the colloidal
suspension that is monitored by its turbidity. Complex
size and shape, lipid composition and formulation, and
encapsulation eﬃciency of nucleic acids by the liposomes
also contribute to the colloidal properties of the complexes.
The colloidal properties aﬀect serum stability, protection
from nuclease degradation, blood circulation time, and
biodistribution of the complexes.
Our in vivo transfection data showed that an adequate
amount of colloids in suspension was required to produce
eﬃcient gene expression in all tissues examined [1]. The col-
loidal suspension is assessed by measurement of adsorbance
at 400nm using a spectrophotometer optimized to measure
turbidity. Our data showed that transfection eﬃciency in all
tissues correlated with OD400 of the complexes measured
prior to intravenous injection.
6. Efﬁcient Disseminationthroughout target
TissuesandMigration acrossTight Barriers
Ap r i m a r yg o a lf o re ﬃcient in vivo delivery is to achieve
extravasation into and penetration throughout the targetJournal of Drug Delivery 5
Figure 5: Cryo-electron micrograph of extruded DOTAP: DOPE
liposomes complexed to plasmid DNA. Although these lipo-
somes were prepared by the same protocol that produces BIV
DOTAP:Chol, these vesicles cannot wrap and encapsulate nucleic
acids. The DNA condenses on the surfaces of the liposomes shown.
organ/tissue ideally by minimally invasive systemic adminis-
tration. Without these events, therapeutic eﬃcacy is highly
compromised for any treatment including gene and drug
therapies. Achieving this goal is diﬃcult due to the many
tight barriers that exist in animals and people. Furthermore,
many of these barriers become tighter in the transition
from neonates to becoming adults. Penetration throughout
an entire tumor is further hindered due to the increased
interstitial pressure within most tumors [35–37]. We believe
that nonviral systems can play a pivotal role in achieving
target organ extravasation and penetration needed to treat
or cure certain diseases. Our preliminary studies have shown
that extruded BIV DOTAP:Chol nucleic acid:liposome
complexes can extravasate across tight barriers and penetrate
evenly throughout entire target organs, whereas viral vectors
cannotcrossidenticalbarriers.Asstatedabove,thesebarriers
include the endothelial cell barrier in a normal mouse [18,
38], the posterior blood retinal barrier in adult mouse eyes
[38], complete and homogeneous diﬀusion throughout large
tumors [18, 38], and penetration through several tight layers
of smooth muscle cells in the arteries of pigs [38]. Diﬀusion
throughout large tumors was measured by expression of ß-
galactosidase or the proapoptotic gene p53 in about half
of the p53-null tumor cells after a single injection of BIV
DOTAP:Chol-DNA liposome complexes into the center of
a tumor. Transfected cells were evenly spread throughout
the tumors. Tumors injected with complexes encapsulating
plasmid DNA encoding p53 showed apoptosis in almost all
ofthetumorcellsbyTUNELstaining.Tumorcellsexpressing
p53 mediate a bystander eﬀect on neighboring cells perhaps
due to upregulation by Fas ligand that causes nontransfected
t u m o rc e l l st ou n d e r g oa p o p t o s i s .
7. Charge versus Delivery
Our delivery system is eﬃcient because we have optimized
the overall charge of complexes to produce the highest
delivery into cells, that is approximately 45.5mV measured
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Cell entry of complexes
Figure 6: Mechanisms for cell entry of nucleic acid-liposome
complexes. Two major pathways for interaction are by endocytosis
or by direct fusion with the cell membrane. Complexes that enter
the cell by direct fusion allow delivery of more nucleic acids to
the nucleus because the bulk of the nucleic acids do not enter
endosomes.
by a zeta potential analyzer [9]. Our complexes deliver
DNA into cells by fusion with the cell membrane and
thereby avoid the endocytic pathway (Figure 6). Cells are
negatively charged on the surface, and speciﬁc cell types
vary in their density of negative charge. These diﬀerences in
charge density can inﬂuence the ability of cells to be trans-
fected. Cationic complexes have nonspeciﬁc ionic charge
interactions with cell surfaces. Eﬃcient transfection of cells
by cationic complexes is, in part, contributed by adequate
charge interactions. In addition, other publications report
that certain viruses have a partial positive charge around key
subunits of viral proteins on the virus surface responsible
for binding to and internalization through target cell surface
receptors [39–44]. Therefore, this partial positive charge is
required for virus entry into the cell. Thus, maintenance
of adequate positive charge on the surface of targeted
BIV complexes is essential for optimal delivery into the
cell. Diﬀerent formulations of liposomes interact with cell
surfaces via a variety of mechanisms. Two major pathways
for interaction are by endocytosis or by direct fusion with
the cell membrane [33, 45–50]. Preliminary data suggest
that nucleic acids delivered in vitro and in vivo using BIV
complexesdevelopedinourlabenterthecellbydirectfusion.
Apparently, with our delivery vehicle, the bulk of the nucleic
acids do not enter endosomes, and, therefore, the bulk of
nucleic acids enter the nucleus more rapidly. Fusogenic cell
transfection produced orders of magnitude increased levels
ofgeneexpressionandincreasednumbersofcellstransfected
versus cells transfected through the endocytic pathway.
8.Reversible Masking
However, the positive charge on the surface of delivery
vehicles also results in uptake in nontarget cells as well.
Therefore, the charge must be shielded brieﬂy until the
complexes arrive at the target cell. As stated above, we believe
that maintenance of adequate positive charge on the surface
of complexes is essential to drive cell entry by direct fusion.
Therefore, we created a methodology to achieve targeted
delivery of our complexes in vivo without the use of PEG.
These ligand-coated BIV complexes reexpose the overall6 Journal of Drug Delivery
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Figure 7: Optimized strategy for delivery and gene expression in the target cell. Optimization of many steps is required to achieve targeted
delivery, shielding from nonspeciﬁc uptake in nontarget organs and tissues, deshielding, fusion with the cell membrane, entry of nucleic
acids into the cell and to the nucleus, and production of gene expression of a cDNA cloned in a plasmid.
positive charge of the complexes as they approach the target
cells. In addition, through covalent attachments, we have
added small molecules to the surface of our preformed com-
plexes that mimic protein-protein interactions [9]. These
small molecules eﬃciently bind to the target cell surface
receptor and maintain entry into the cell by direct fusion.
Furthermore, we showed that using this novel method of
addition of ligands to the complexes for targeted delivery
results in further increased gene expression in the target
cells after transfection. Therefore, this design of a targeted
liposomal delivery system retains predominant fusogenic cell
entryratherthantheendocytictransport.Figure 7showsour
optimized strategy to achieve targeted delivery, deshielding,
fusionwiththecellmembrane,entryofnucleicacidsintothe
cell and to the nucleus, and production of gene expression of
a cDNA cloned in a plasmid.
Much eﬀort has been made to speciﬁcally deliver nucleic
acid-liposome complexes to target organs, tissues, and/or
cells. Ligands that bind to cell surface receptors are usually
attached to PEG and then attached to the cationic or
anionic delivery vehicle. Due to shielding of the positive
charge of cationic complexes by constitutively incorporated
PEG, delivery to the speciﬁc cell surface receptor can be
accomplished by only a small fraction of complexes injected
systemically. Furthermore, delivery of PEGylated complexes
into the cell occurs predominantly through the endocytic
pathway, and subsequent degradation of the bulk of the
nucleic acid occurs in the lysosomes. Thus, gene expression
is generally lower in the target cell than when using the
nonspeciﬁc delivery of highly eﬃcient cationic complexes.
Recent eﬀorts to use cleavable PEG are unimpressive and
have not solved these problems (Table 1)[ 10, 12–17, 32].
As discussed above, the vast majority of the injected
PEGylated complexes bypass the target cell, including those
using cleavable PEG. Apparently, the PEGylated complexes
cannot utilize critical charge interactions for optimal trans-
fection into cells by direct fusion due to the overall low
or neutral charge. The inability to expose positive charge
on the surface of optimized delivery vehicles results in the
transfection of fewer cells. PEGylation was ﬁrst used to
increase the half-life of complexes in the circulation and
to avoid uptake in the lung. However, this technology also
destroys the ability to eﬃciently transfect cells. We were
able to increase the half-life in circulation of BIVs to ﬁve
hours without the use of PEG. Because the extended half-
life of BIVs is not too long, this delivery system does
not result in the accumulation of complexes in nontarget
tissues that occurs with circulation half-lives of one to three
days as seen with PEGylated liposomal delivery systems.
Some investigators have now reported targeted delivery that
produces increased gene expression in the target cell over
their nontargeted complexes. However, these nontargeted
and targeted delivery systems are ineﬃcient [51]c o m p a r e d
to eﬃcient delivery systems such as the BIVs.
In using the extruded BIV DOTAP:Chol nucleic
acid:liposome complexes, we produced an optimal half-life
in the circulation without the use of PEG [9]. Extended half-
life was produced primarily by the formulation, preparation
method, injection of optimal colloidal suspensions, serum
stability,andoptimalnucleicacid:lipidratiousedformixing
complexes, and size (200 to 450nm). Furthermore, we avoid
uptake in the lungs using the negative charge of the ligands
and “shielding/deshielding compounds” that can be added
to the complexes used for targeting just prior to injection orJournal of Drug Delivery 7
Table 1 :C o m p a r i s o no fr e c e n t ,i m p r o v e dt a r g e t e dd e l i v e r ys y s t e m s .
NP∗ type Increase
to NT∗∗
Decrease
to NT∗∗∗ Eﬃcacy of targeted delivery system
BIVs + small molecules + reversible masking 200-fold None Complete elimination of aggressive, orthotopic pancreatic
cancers after 5 iv injections administered once a week [9]
RTNs with endosomally cleavable PEG 2-fold None 75% reduction in subcutaneous neuroblastoma tumor size
after 7 iv injections administered every 48h [10, 11]
MEND + pH-sensitive fusogenic peptide or a cell
penetrating peptide + cleavable PEG None 2-fold None reported [12, 13]
FRT + cleavable PEG 1-fold None None reported [14]
Copolymers + cleavable PEG None None None reported [15]
Liposomes + cell penetrating peptide + cleavable PEG 1.3-fold None None reported [16, 17]
∗Nanoparticle (NP).
∗∗Nontargeted (NT); increased delivery of the targeted NP to the target compared with the corresponding nontargeted formulation.
∗∗∗Nontargeted (NT); decreased delivery of the targeted NP to the target compared with the corresponding nontargeted formulation.
administration in vivo. Our strategy to bypass nonspeciﬁc
transfection is called reversible masking (US Patent no.
7,037,520 B2) [9] which allows for charge reexposure facil-
itated by ﬁrst-pass circulatory sheering forces. As discussed
above, we believe that use of small molecules for targeted
deliveryisideal,andsmallerligandsrequiretheuseofsmaller
reversible masks. Therefore, we accomplished decreasing the
overall charge of BIV complexes by adding the small neutral
lipid, n-dodecyl-β-D-maltopyranoside, approximately 511
MW,justpriortoivinjections[9](Templeton,N.S.USPatent
no. 7,037,520 B2 issued May 2, 2006). By addition of ligands
using the novel approaches that we developed, adequate
overall positive charge on the surface of complexes at the
target site is preserved. In summary, we achieve optimal
circulation time of the complexes, reach and deliver to the
targetorgan,avoiduptakeinnontargettissues,andeﬃciently
interactwiththecellsurfacetoproduceoptimaltransfection.
We have developed a multidisciplinary approach com-
bining molecular biology, delivery technology, combinato-
rial chemistry, and reversible masking to create improved
systemic, targeted delivery of plasmid DNA while avoiding
nonspeciﬁcuptakeinvivo.Weappliedthistechnologytoeﬃ-
ciently target delivery to a human tumor-microenvironment
model. We achieved eﬃcient, targeted delivery by attach-
ment of speciﬁc targeting ligands to the surface of our
BIV complexes in conjunction with reversible masking to
bypass nonspeciﬁc tissues and organs. We identiﬁed ligands
that target a human tumor-microenvironment created in
vitro by coculturing primary human endothelial cells with
human lung or pancreatic cancer cells. The model was
conﬁrmed by increased expression of tumor endothelial
phenotypes including CD31 and VEGF-A and prolonged
survival of endothelial capillary-like structures. The cocul-
tures were used for high-throughput screening of a spe-
cialized small-molecule peptidomimetic library to identify
ligands speciﬁc for human tumor-associated endothelial
cells in vitro. We identiﬁed small molecules that enhanced
the transfection eﬃciency of tumor-associated endothelial
cells, but not normal human endothelial cells or cancer
cells. IV administration of our targeted, reversibly masked
complexes into mice, bearing human pancreatic tumor and
endothelial cells, speciﬁcally increased transfection to this
tumor microenvironment about 200-fold. Eﬃcacy studies
using our optimized targeted delivery of a plasmid encoding
thrombospondin-1 eliminated tumors completely after ﬁve
intravenous injections administered once weekly. We plan to
use our targeted, reversibly masked delivery system in the
clinic to treat metastatic cancer.
Table 1 compares reversible masking versus the cleavable
PEG systems. None of the cleavable PEG systems have
shown the exceptionally high, 200-fold increased targeted
delivery demonstrated by BIVs coated with small molecule
B-turn mimics for speciﬁc delivery to the target cell and
reversible masking to avoid nonspeciﬁc uptake described
above. Furthermore, we achieve this high level of targeted
delivery without the use of peptides that are known to
be immunogenic when multimerized on the surface of
delivery vehicles and then repeatedly injected iv. In addition,
we demonstrated greater eﬃcacy than these other delivery
systems, i.e., complete elimination of aggressive, orthotopic
pancreatic cancers after 5 iv injections administered once
a week. At best, the receptor-targeted nanocomplex (RTN)
withendosomallycleavablePEGandRGDintegrin-targeting
peptide showed only a 2-fold increased delivery to subcuta-
neous neuroblastoma tumors [11]. Furthermore, only a 75%
reduction in tumor size after 7 iv injections administered
every 48h was achieved using this optimized formulation.
Targeted delivery systems can also be less eﬃcient in delivery
to the target compared to the non-PEGylated, nontargeted
formulations as shown for the MEND system (Table 1)[ 12,
13, 32]. Not surprising, no eﬃcacy in any disease model
has been reported for this delivery system. In summary, we
have deﬁned and distinguished our novel reversible masking
versus PEGylation and demonstrated its superior use for
avoiding nonspeciﬁc uptake in vivo.
Abbreviations
BIV: Bilamellar invaginated vesicle
NP: Nanoparticle
Iv: Intravenous
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